

# The Future of atrial fibrillation management. Integrated care and stratified therapy

Kirchhof, Paulus

DOI:

[10.1016/S0140-6736\(17\)31072-3](https://doi.org/10.1016/S0140-6736(17)31072-3)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Kirchhof, P 2017, 'The Future of atrial fibrillation management. Integrated care and stratified therapy', *The Lancet*. [https://doi.org/10.1016/S0140-6736\(17\)31072-3](https://doi.org/10.1016/S0140-6736(17)31072-3)

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

Eligibility for repository: Checked on 5/5/2017

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Clinical Seminar: The Future of atrial fibrillation management. Integrated care and stratified therapy**

Paulus Kirchhof, MD<sup>1-3</sup>

1 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

2 Sandwell and West Birmingham Hospitals NHS trust and University Hospitals Birmingham NHS Foundation NHS trust, Birmingham, United Kingdom

3 Atrial Fibrillation NETwork, Muenster, Germany

Word count (text without tables and without references): 4591

**Correspondence address:**

Professor Paulus Kirchhof  
Institute of Cardiovascular Sciences  
IBR 136  
University of Birmingham  
Wolfson Drive  
Birmingham, B15 2TT  
United Kingdom  
Telephone: +44 121 414 7042  
Fax: +44 121 414 5788  
e-mail: p.kirchhof@bham.ac.uk

**Abstract**

Atrial fibrillation is one of the major cardiovascular health problems: It is a common, chronic condition, affecting 2-3% of the populations in Europe and the USA and requiring 1-3% of health care expenditure due to stroke, sudden death, heart failure, unplanned hospitalizations, and other complications. Early diagnosis of AF, ideally before the first complication occurs, remains a challenge, illustrated by patients who are only diagnosed with AF when hospitalized for acute cardiac decompensation or stroke. Once diagnosed, AF requires chronic, multidimensional management in five domains (acute management, treatment of underlying and concomitant cardiovascular conditions, stroke prevention therapy, rate control, and rhythm control). Providing these treatment options consistently to all AF patients remains challenging, despite recent improvements. Integrated care models providing patient-centred care in or close to the community while maintaining access to all specialist treatment options emerge as the best approach to achieve consistent delivery of these chronic treatments to all AF patients in need of better management. Ongoing research efforts will determine when to initiate oral anticoagulation in patients with device-detected atrial high rate episodes, quantify the prognostic impact of early and comprehensive rhythm control therapy including AF ablation, and delineate optimal methods to reduce bleeding complications in anticoagulated AF patients. In addition, research efforts are needed to define different types of AF based on the main causes of AF in a given patient to pave the way for the clinical development of stratified AF therapy.

**The atrial fibrillation epidemic.** Atrial fibrillation (AF) affects 2-3% of the populations in Europe<sup>1-3</sup>, and more than 1% of the entire health care expenditure is spent on AF management.<sup>4,5</sup> Less than one in 200 persons below 50 years of age, but more than one in ten in populations aged 80 or above suffer from AF.<sup>1-3</sup> Thirteen to 21 percent of the populations in Europe are aged 65 years or older today (<http://data.org/search.aspx?q=age>), and we enjoy ever longer lives. The projected population ageing, combined with an accumulation of chronic non-communicable cardiovascular diseases and risk factors<sup>6</sup>, will lead to a dramatic increase of AF patients in the coming years. This AF epidemic and the severe complications associated with AF (Table 1A) render atrial fibrillation one of the major threats to cardiovascular health.<sup>7</sup>

**Table 1A: Common symptoms and complications of atrial fibrillation.** Silent AF that does not cause symptoms but still leads to complications is not uncommon. Treatment can prevent many, but not all AF-related complications. Most symptoms and consequences of AF are interrelated and thus complications and symptoms can link across lines in this table.

Symptoms of AF	Related complication of AF	Treatment to prevent symptoms and complications
-	Stroke	Treatment of underlying conditions, oral anticoagulation, possibly left atrial appendage occluders
Fatigue or tiredness	Depression, reduced quality of life	? (possibly rhythm control)
Shortness of Breath	Impaired autonomy, worsening of cardiac function, unplanned hospitalizations	ACE inhibitors, rate control, possibly rhythm control
Palpitations	Tachycardiomyopathy, reduced autonomy	Rate control, rhythm control, possibly anticoagulation
Chest pain	Acute coronary syndrome, unplanned hospitalizations	Treatment of underlying conditions, possibly anticoagulation
Depressed mood, anxiety	Frequent hospitalizations, Impaired cognitive function	Possibly rate control and rhythm control Possibly oral anticoagulation

**Table 1B: The modified EHRA symptoms scale (mEHRA scale)** to describe severity of AF-related symptoms in a semi-quantitative fashion. Modified from Wynn et al<sup>8</sup> and recommended for use by the European Society of Cardiology.<sup>2</sup>

mEHRA scale	Symptoms	Description
<b>1</b>	None	AF does not cause any symptoms (includes silent AF)
<b>2a</b>	Mild	Normal daily activity not affected by symptoms related to AF <sup>a</sup>
<b>2b</b>	Moderate	Normal daily activity not affected, but patient troubled by symptoms <sup>a</sup>
<b>3</b>	Severe	Normal daily activity affected by AF

4	Disabling	Normal daily activity discontinued due to AF
---	-----------	--

AF = atrial fibrillation; EHRA = European Heart Rhythm Association.

**Clinical presentation and AF-related symptoms.** AF is a common cause of ischemic stroke.<sup>2</sup> In AF patients on oral anticoagulation, stroke is relatively infrequent (1.5% per year in trials)<sup>9,10</sup>, but worsening of heart failure and sudden death remain common even in adequately treated AF patients.<sup>11,12</sup> Common symptoms in AF patients are fatigue or shortness of breath, as well as palpitations<sup>13-18</sup>, but also anxiety<sup>19</sup> and a depressed mood.<sup>20-23</sup> These symptoms may be especially pronounced during the initial presentation. Furthermore, stroke, heart failure, or even sudden death can constitute the initial presentation of AF patients. Sudden death can be a consequence of underlying cardiac diseases, e.g. inherited cardiomyopathies<sup>24,25</sup> or heart failure<sup>26</sup>, but may also be a consequence of the irregular ventricular activation pattern in AF. Every 4<sup>th</sup> to 5<sup>th</sup> AF patient is admitted to hospital in a year.<sup>14,16,27,28</sup> Hospitalizations are most commonly triggered by symptomatic AF, but also reflect that AF patients often suffer other cardiovascular conditions that require in-patient therapy.

Importantly, many patients do not experience any AF-related symptoms (“silent AF”), and a stroke may be the first presentation of AF.<sup>29,30</sup> Silent AF is common: When systematic ECG monitoring is applied to patients with symptomatic AF, around 70% of AF episodes are silent.<sup>31</sup> Patients with silent AF are still at risk of stroke, heart failure or sudden death, illustrating the public health importance of detecting silent AF.<sup>32,33</sup>

**ECG screening in populations to diagnose silent AF.** Unfortunately, AF is often not diagnosed before the first stroke: Approximately 5% of unselected patients admitted to stroke units present with overt (usually chronic) AF on admission.<sup>29</sup> Detecting AF prior to the first stroke should therefore be a public and individual health priority. “Opportunistic” screening for AF, i.e. pulse palpation followed by ECG in those with an irregular pulse<sup>35</sup>, is recommended by AF guidelines in all patients aged 65 or more.<sup>2,36</sup> Initial experience with systematic ECG screening in elderly populations using patient-operated devices seems promising<sup>32,37</sup>, but more research is needed before population-wide ECG screening can be recommended.

**ECG screening in stroke survivors.** ECG screening for silent AF has been extensively evaluated in survivors of a stroke or transient ischemic attack. ECG monitoring for a few days identifies silent AF in an additional 5% of unselected patients admitted to stroke units.<sup>29,38</sup> Longer ECG monitoring identifies even more patients with AF (5 – 25% additional yield)<sup>29,30,39</sup>, especially in patients with “cryptogenic stroke”<sup>38,40,41</sup> or “embolic stroke of unknown source” (ESUS).<sup>42</sup> ECG monitoring for at least 72 hours is recommended in stroke survivors and in at-risk populations.<sup>2</sup> Recently, one of the first randomized studies confirmed that longer ECG monitoring results in a higher detection rate of AF in stroke survivors (13.5% vs. 4.5%).<sup>43</sup> Ongoing studies evaluate the effect of ECG screening in stroke survivors on uptake of anticoagulation and prevention of strokes.<sup>44</sup> Based on the high prevalence of silent AF, ongoing trials evaluate whether oral anticoagulation should be used in all patients with an embolic stroke of unknown etiology, irrespective of heart rhythm.<sup>45,46</sup>

**Management of patients with AF detected by ECG screening.** Detection of silent AF has immediate consequences for antithrombotic therapy: Most patients with incidentally diagnosed AF, or with AF detected by systematic ECG screening, will have stroke risk factors that render them eligible for oral anticoagulation.<sup>2,32,35</sup> Patients with silent AF should also be investigated for concomitant cardiovascular conditions that require therapy.<sup>2</sup> Rhythm control therapy is not required in patients

with silent AF, unless they develop AF symptoms. Periodic reassessment for symptoms and complications of AF is advisable.

**Management of patients with atrial high episodes detected by implanted devices.** Importantly, all AF therapies have been evaluated in patients with ECG-documented AF. Thus, atrial arrhythmias detected by other methods, e.g. an irregular pulse detected by blood pressure machines or by an optical device, or atrial high rate episodes (AHRE) detected by a pacemaker, require verification of AF by ECG before initiating AF therapy.<sup>2</sup> Importantly, not all atrial AHRE detected by implanted devices are AF.<sup>47,48</sup> Furthermore, there is good data to show that the stroke risk is lower in patients with AHRE, but without ECG-documented AF, than in patients with AF. Consequently, we cannot know whether patients with AHRE benefit from oral anticoagulation. Ongoing controlled trials such as ARTESiA (NCT01938248) and NOAH – AFNET 6 (NCT02618577) currently evaluate the benefit and risk of oral anticoagulation in patients with atrial high rate episodes.

### **The five domains of atrial fibrillation management.**

Atrial fibrillation requires attention to five domains of management, where each treatment component targets different components of the heart (Figure 1). These five domains of AF management are: Acute stabilization of patients who present with AF complications or hemodynamic compromise, detection and treatment of underlying and accompanying cardiovascular conditions, stroke risk assessment and in most patients oral anticoagulation for stroke prevention, rate control, and rhythm control therapy in symptomatic patients (Figure 2). Acute stabilization, treatment of concomitant conditions, and stroke prevention carry prognostic benefits. Rate control and rhythm control therapy can help to maintain left ventricular function but are mainly used to improve AF-related symptoms. All domains have the potential to maintain functional integrity of the heart (Figure 1).

### **Detection and management of concomitant cardiovascular conditions: Hypertension, heart failure, valvular heart disease, diabetes, coronary and other arterial vascular disease, and others**

The presence of atrial fibrillation should be taken as a strong suggestion that other cardiovascular conditions are present. To detect such conditions, a careful cardiovascular examination and an echocardiogram should be performed in all AF patients at the time of diagnosis. Comprehensive diagnosis and treatment of cardiovascular risk factors and concomitant diseases<sup>51</sup> should be an integral part of AF management.

*Hypertension* is common in AF patients. Adequate control of blood pressure reduces stroke risk, bleeding risk on anticoagulation, and probably recurrences of AF. ACE inhibitors and sartans appear to prevent AF slightly better than other hypertensive agents, especially in patients with left ventricular hypertrophy or heart failure,<sup>52,53</sup> but by and large antihypertensive agents can be used as recommended for hypertensive patients in general.

*Heart failure* and AF often coexist.<sup>54</sup> The management of patients with AF and heart failure requires simultaneous treatment of both AF<sup>2</sup> and heart failure<sup>55</sup>, including acute control of rate and urgent cardioversion in hemodynamically compromised patients, diuretic therapy in patients with fluid overload, initiation of anticoagulation, and inhibition of the renin-angiotensin-aldosterone system.<sup>56</sup> Beta blockers can be safely used, but their prognostic benefit seems lost in patients with AF and heart failure.<sup>57</sup> It is often difficult to distinguish symptoms of heart failure from AF symptoms in the

acute setting, especially in patients with preserved or moderately impaired ejection fraction. A careful reconstruction of symptoms and disease signs over time often helps, and occasionally restoration of sinus rhythm is useful to distinguish AF-related symptoms from heart failure.

*Valvular heart disease*, especially mitral or aortic valve disease, can become more symptomatic when AF develops. New onset AF is regarded as a sign for progressive atrial damage, and is one of the factors that should be considered to determine the best time point for valve surgery. Patients with rheumatic heart disease<sup>2</sup> have not been tested in the NOAC trials programmes. Patients with mechanical heart valves<sup>58</sup> require vitamin K antagonists for oral anticoagulation.

*Obesity* contributes to recurrent AF, possibly via activation of adipocytes in the atria and/or by fatty infiltration of atrial myocardium.<sup>59,60</sup> Weight reduction and increased general fitness help to prevent AF in obese patients, and can even obviate the need for catheter ablation.<sup>61-63</sup>

*Coronary artery disease* can be managed with an anticoagulant without further antiplatelet therapy in stable patients. After stenting or an acute coronary syndrome, the added bleeding risk of combined antiplatelet and anticoagulant therapy needs to be balanced against the need to prevent recurrent thrombo-embolic events. Usually, this can be achieved by short-term combination therapy for 1-12 months, currently consisting of an anticoagulant, clopidogrel, and probably aspirin.<sup>2,64-66</sup> Ongoing studies will inform about the safety of other combination therapies with non-vitamin K antagonist oral anticoagulants and newer antiplatelet agents.<sup>67</sup> Most other treatments for coronary artery disease can readily be combined with AF therapy.

### **Oral anticoagulation for stroke prevention.**

The combination of a local prothrombotic milieu in the left atrium, systemic activation of coagulation, blood stasis in the atria, and expression of prothrombotic factors on the atrial endothelium all contribute to clot formation in patients with atrial fibrillation.<sup>68-70</sup> The annual stroke risk in non-anticoagulated AF patients is between <1% and >10%.<sup>69,70</sup> Oral anticoagulation therapy with vitamin K antagonists or non-vitamin K antagonist oral anticoagulants (NOACs) prevents most ischemic strokes in patients with atrial fibrillation at risk for stroke, translating into preserved independence and autonomy for patients, lower morbidity, and longer lives in AF patients at high stroke risk.<sup>9,10</sup> Antiplatelet therapy does not prevent strokes in AF patients. AF patients with two or more clinical stroke risk factors (Table 2A) benefit from oral anticoagulation, especially those at higher age (e.g. > 75 years) and survivors of a stroke, but also those with heart failure, hypertension, diabetes mellitus (especially when requiring insulin therapy), or vascular disease. Conversely, patients at low risk of stroke do not require antithrombotic therapy, i.e. those without clinical stroke risk factors, and some patients with one of the clinical stroke risk factors<sup>2,71</sup>.

Oral anticoagulation is not without side effects: Approximately 2% of anticoagulated AF patients experience a major bleeding event per year of exposure to anticoagulants.<sup>72,73</sup> Modifiable bleeding risk factors should therefore be reduced in all anticoagulated AF patients (Table 2B) to minimise bleeding. Many bleedings have a treatable cause, e.g. bleeding due to gastric ulcers or cerebral aneurysms, and such causes should be identified and treated promptly in AF patients in need for anticoagulation. Importantly, most patients with a high bleeding risk are also at high risk of stroke and will benefit from anticoagulation.<sup>2</sup> Recent data suggest that selected biomarkers, e.g. troponin, BNP, or markers of kidney disease, can be used to refine stroke risk estimation in selected patients, although further data are needed to inform their use in routine care.<sup>2,74,75</sup>





**Table 2A Clinical risk factors for stroke in patients with atrial fibrillation** as validated in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score for stroke risk estimation in patients with atrial fibrillation.

Clinical stroke risk factor	Definition and explanation
<b>Congestive heart failure</b>	Signs or symptoms of heart failure or evidence of reduced left ventricular ejection fraction
<b>Hypertension</b>	Resting blood pressure > 140/90 mmHg on at least two occasions or current antihypertensive treatment
<b>Increasing age</b>	Stroke risk continuously increases with age. Most stroke risk scores define age strata (e.g. ≥ 65 years or ≥ 75 years) to simplify stroke risk estimation
<b>Diabetes mellitus</b>	Fasting glucose > 125 mg/dL or treatment with hypoglycaemic agents, especially when patients require insulin for diabetes management
<b>Previous stroke, transient ischemic attack, or thromboembolism</b>	A prior stroke or transient ischemic attack, together with older age, is probably the strongest clinical stroke risk factor in patients with atrial fibrillation.
<b>Vascular disease</b>	Previous myocardial infarction, peripheral artery disease, or aortic plaque
<b>Female sex</b>	Female patients with AF appear to have a higher stroke risk than male patients when other risk factors are present. In patients with only one or two of the clinical stroke risk factors, female AF patients do not appear to have an increased stroke risk. <sup>2,71</sup>

CHA<sub>2</sub>DS<sub>2</sub>-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female).

**Table 2B: Modifiable bleeding risk factors in anticoagulated AF patients, their definition, and interventions to minimize these bleeding risk factors.** Modifiable bleeding risk factors have been extracted from several validated bleeding risk scores.<sup>2</sup>

Modifiable bleeding risk factors	Definition, explanation	Proposed intervention
<b>Concomitant therapy with antiplatelet agents or nonsteroidal anti-inflammatory medications</b>	Including over the counter medication and paracetamol. Selected patients, e.g. those requiring stenting or those at risk of a recurrent acute coronary syndrome, require short term combination therapy.	Avoid co-medication, advise patients of risk
<b>Uncontrolled hypertension</b>	Blood pressure > 160/90 mmHg during office measurements, and uncontrolled blood pressure peaks	Treat hypertension adequately
<b>Labile INR values in patients treated with vitamin K antagonists</b>	Most often measured as a low time in therapeutic range	Control INR better (including self-measurement), change to a NOAC
<b>Excess alcohol use</b>	Daily alcohol consumption, consumption of more than 65g – 110g of alcohol per week (8 - 14 units)	Reduce alcohol consumption, provide access to behaviour changing programmes

Several oral anticoagulants are effective and approved for stroke prevention in AF. Four different vitamin K antagonists and four non-vitamin K antagonist oral anticoagulants (NOACs) are available and allow to select an appropriate oral anticoagulant in most patients with AF (Table 3).<sup>2,76</sup> Aspirin does not prevent ischemic stroke in AF patients. Of note, there is a tendency to prescribe lower doses of NOACs than those that were tested and approved in controlled trials, which seems associated with higher complication rates.<sup>73</sup> Oral anticoagulation can often be initiated by adequately trained general practitioners, especially when they form part of a larger network providing integrated AF care, and may be guided by IT tools to ensure appropriate selection of eligible patients for anticoagulation and for a specific dose of an anticoagulant. NOACs therapy is less likely to cause bleeding, especially intracranial hemorrhage, rendering them preferable over vitamin K antagonists in eligible patients.<sup>10</sup> In selected patients with true contraindications to any form of oral anticoagulation, interventional or surgical left atrial appendage occlusion can be considered as an alternative to oral anticoagulation.<sup>77-81</sup> Difficult anticoagulation decisions should be informed by a multidisciplinary AF Heart Team involving anticoagulation specialists, stroke neurologists, and experts in occluder therapy.<sup>2</sup>

Despite the proven benefits of oral anticoagulation in AF patients, many patients with AF at risk for stroke do not receive oral anticoagulation or discontinue oral anticoagulants soon after initiation.<sup>82-88</sup> Major bleeding events, e.g. gastro-intestinal, hypertensive or intracranial bleeds, are one of the major reasons to discontinue oral anticoagulation.<sup>82,84,89-92</sup> A short interruption of anticoagulation is usually required to manage acute bleeding events.<sup>2,76</sup> Once the cause of bleeding has been eliminated (e.g. treatment of a gastric ulcer, clipping or coiling of an arterial malformation, optimization of antihypertensive therapy, see also Table 2B), oral anticoagulation should probably be reinitiated in most AF patients at risk for stroke.<sup>93,94</sup> Information of AF patients about their therapy, leading to patients who “own” and participate in AF management, has the potential to improve this situation.<sup>95-97</sup> To improve continuation of chronic therapy, integrated AF management models should be developed (see below).

**Table 3: Oral anticoagulants and interventional stroke prevention treatment in AF patients.**

Dose		Dose reduction
Vitamin K antagonists		
Warfarin	typical dose 1 – 5 mg OD	Individual dose aiming at an international normalized ration (INR) of 2-3
Phenprocoumon	typical dose 0.5 – 3 mg OD	
Fluindione	typical dose 5 – 30 mg OD	
Acecoumarol	typical dose 2 – 4 mg OD	
Non-vitamin K antagonist oral anticoagulants		
Apixaban	5 mg BD	2.5 mg BD in patients fulfilling two of the following criteria: serum creatinine > 1.5 mg/dl, age 80 > 80 years, weight > 60 kg Apixaban has not been tested in patients with a baseline creatinine clearance < 25 ml/min.
Dabigatran	110 mg BD 150 mg BD	In Europe, a dose of 110 mg BD is suggested in patients > 75 years of age* Dabigatran has not been tested in patients with a baseline creatinine clearance < 30 ml/min.
Edoxaban	60 md OD	30 mg OD if creatinine clearance < 50 ml/min Edoxaban has not been tested in patients with a baseline creatinine clearance < 30 ml/min.
Rivaroxaban	20 mg OD	15 mg OD if creatinine clearance is < 50 ml /min Rivaroxaban has not been tested in patients with a baseline creatinine clearance < 30 ml/min.
Left atrial appendage occlusion		
Interventional left atrial appendage occlusion	The interventional procedure carries a risk of complications (tamponade, stroke, vascular access complications). Several post-interventional antithrombotic therapy regimes have been evaluated.	
Surgical occlusion of the left atrial appendage	Surgical atrial occlusion or exclusion does not add much to the risk of cardiac surgery when performed concomitant with open heart surgery. There is a small risk of bleeding and tamponade, and a risk of incomplete occlusion.	

\*In the USA, dabigatran is not approved for stroke prevention in AF at the 110 mg BD dose. The FDA has also approved dabigatran 75 mg BD for stroke prevention in AF patients on dialysis.

**Rate control therapy.** During atrial fibrillation, each part of the atrial myocardium is stimulated at a rate of 300 – 400 activations per minute. The rapid reactivation of atrial myocardium leads to atrial contractile standstill in most patients and results in rapid and irregular ventricular rates. Most symptomatic AF patients therefore present with high ventricular rates, and control of ventricular rate is used to improve left ventricular function and AF-related symptoms. Rate control is achieved using beta blockers, digoxin or digitoxin, and verapamil or diltiazem. The initial heart rate target can be lenient (ventricular rate at rest < 110 bpm<sup>98</sup>). There is currently no evidence favouring stricter initial heart rate targets, and no clear evidence linking rate control therapy to better outcomes.<sup>57,99</sup> Rather, current recommendations for rate control therapy are based on small studies with composite outcomes<sup>98,100</sup> and on the therapies evaluated in the rate control arms of the AFFIRM, RACE, and PIAF trials.<sup>101-103</sup> Details of rate control therapy approaches can be found in the 2016 ESC guidelines on AF<sup>2</sup> and in a recent seminar published in the Lancet.<sup>104</sup> Even on adequate rate-control therapy, many AF patients remain symptomatic, thus requiring adaptation of rate control therapy and/or rhythm control therapy on top of rate control (see next section).

**Rhythm control therapy.** Restoring and maintaining sinus rhythm in AF patients can improve AF-related symptoms. There is no sign so far that rhythm control therapy improves outcomes in AF patients. Cardioversion, antiarrhythmic drugs, and catheter or surgical AF ablation are available for

this type of therapy. Ongoing controlled studies such as CABANA (NCT00911508) and EAST – AFNET 4 ([www.easttrial.org](http://www.easttrial.org)<sup>105</sup>) will determine whether modern rhythm control therapy (early therapy including the use of catheter ablation) can improve prognosis in AF patients when added to evidence-based anticoagulation and rate control therapy. The current approach to rhythm control therapy is summarized in the 2016 ESC AF guidelines<sup>2</sup> and has recently been reviewed in a seminar in the Lancet.<sup>106</sup> Importantly, rhythm control therapy will benefit from integration into a “holistic”, integrated approach to AF care that also provides treatment of underlying cardiovascular diseases and precipitating factors (e.g. obesity), continued stroke prevention and rate control therapy (see “integrated AF care” below). This will minimize AF recurrences and improve quality of life.

Systematic symptom assessment, e.g. using the modified EHRA score (Table 1B), should guide the use of rhythm control therapy. Cardioversion, pharmacological or electrical<sup>107-109</sup>, long-term<sup>109,110</sup> or targeted short-term<sup>109,111</sup> antiarrhythmic drug therapy, and catheter ablation are the main treatments to restore and maintain sinus rhythm. The choice of antiarrhythmic agent needs to consider concomitant cardiovascular conditions to minimize side effects. Abnormal prolongation of the QRS (by more than 25% of the baseline value<sup>2,109</sup>) and QT (by more than 60 ms<sup>2,110,120</sup>) intervals, during the initiation of antiarrhythmic drug therapy identifies patients at risk for proarrhythmia (Table 4). Amiodarone is more effective than other antiarrhythmic drugs (Table 4,<sup>116,118</sup>) and can be used in patients with AF and reduced left ventricular function<sup>119</sup>, but commonly causes extracardiac side effects. Antiarrhythmic drugs can be combined with catheter ablation (“hybrid rhythm control therapy”) to reduce AF recurrences.<sup>122</sup>

Targeting triggers in, or close to, the pulmonary vein ostia has revolutionised AF ablation,<sup>126</sup> and isolation of the pulmonary veins is the accepted target of contemporary AF ablation procedures.<sup>127,128</sup> When used in experienced centres, first-line ablation therapy is as safe and effective as antiarrhythmic drug therapy in selected patients<sup>129,130</sup>. Catheter ablation is often the treatment of choice in AF patients who had recurrences on antiarrhythmic drug therapy. Catheter ablation is more effective than antiarrhythmic drug therapy in patients with paroxysmal<sup>127</sup> and chronic (persistent or long-standing persistent) AF.<sup>128,132,133</sup> Thus, the AF pattern is not considered a major factor in the decision for AF ablation.<sup>2,128,134</sup> Patients with recurrent AF despite initial ablation therapy should be discussed in a Rhythm Control AF Heart Team. More research is needed to guide the best method of catheter ablation beyond isolation of the pulmonary veins.

**Table 4: Rhythm control therapy options in AF patients.** All rhythm control interventions are clinically indicated to improve AF-related symptoms. Available data suggest an improvement in quality of life by rhythm control therapy.

Rhythm control treatment	Antiarrhythmic effect	Unwanted effects	ECG signs of unwanted effects
<b>Antiarrhythmic drugs</b>			
<b>Dronedaron 400 mg BD</b>	Doubling of sinus rhythm compared to placebo	worsening of severe heart failure, torsades de points and/or heart block (rare)	QT prolongation by > 60 ms on therapy, QT > 0.5 s, higher degree heart block
<b>Flecainide 100 – 150 mg BD</b>		ventricular tachycardia in patients with prior myocardial infarction or heart failure, torsades de points (rare)	Increase of QRS duration by >25% on therapy
<b>Propafenone 150 – 300 mg TD</b>		ventricular tachycardia in patients with prior myocardial infarction or heart failure, torsades de points (rare)	Increase of QRS duration by >25% on therapy
<b>Sotalol 160 mg BD</b>		torsades de points, heart block, accumulation in acute kidney failure, increased proarrhythmia risk in left ventricular hypertrophy and heart failure	QT prolongation by > 60 ms on therapy, QT > 0.5 s, higher degree heart block
<b>Amiodarone 200mg OD (loading required over several weeks)</b>	More effective than other antiarrhythmic drugs in maintaining sinus rhythm	High rate of extra-cardiac side effects (thyroid and liver dysfunction, light sensitivity, peripheral neuropathy), torsades de points and/or heart block (rare)	QT > 0.5 s, higher degree heart block
<b>Interventional therapy</b>			
<b>Pulmonary vein isolation using cryoballoon or radio frequency energy</b>	Slightly more effective than antiarrhythmic drugs as first-line therapy, often requiring 2 or 3 procedures, clearly more effective in patients who had recurrent AF on antiarrhythmic drugs	periprocedural stroke, cardiac tamponade, oesophageal fistula, phrenic nerve palsy, brain white matter lesions, vascular damage, radiation exposure	n.a.
<b>Additional ablation, e.g. linear lesions, ablation of specific electrogram patterns, etc.</b>	Effective for post-ablation tachycardias, effectiveness for AF unclear	Same as pulmonary vein isolation, probably higher complication risk due to longer and less standardized procedures	n.a.
<b>Surgical AF ablation</b>	Slightly more effective than catheter ablation	Sinus node dysfunction, pneumothorax, cardiac tamponade, stroke	n.a.

**Integrated AF management, access to all therapy options, and the need to develop stratified AF therapy.**

**The need for integration and differentiation of AF management.** Implementation of the recent advances in AF management, e.g. access to medications that require specialist initiation or interventional and surgical therapy options, is not universal, as illustrated by the variable use of evidence-based treatments in recent observational data sets.<sup>12,15,16,73,137</sup> Furthermore, AF requires chronic management in a large population of patients, including provision of specialist treatment options when needed. Integrated, patient centred approaches to AF care are thus being developed to provide access to all forms of treatment and to ensure continuous management for all AF patients<sup>2,95,96</sup>, transferring concepts tested in other areas of medicine.<sup>138-140</sup> The size of the AF population calls for a staged approach to provide access to AF management for all patients. In fact, the first “nurse-led” models of integrated AF care were at least partially designed to cope with the sheer number of AF patients in need for advice and monitoring.<sup>97</sup>

**Integrated AF care.** Integrated AF care can be described as a care model that is open to all AF patients while providing an efficient infrastructure delivering care in all required treatment domains (Figure 3). Integrated AF care seems more timely now than ever, as more and more patients are in need for AF care (see section on AF screening above, and<sup>1-3</sup>), while on the other hand subspecialist treatment options including stratified approaches to treatment are entering clinical practice. The best patterns of integrated AF care models will vary regionally, and there may be opportunities to merge integrated AF care services with other programmes, e.g. integrated heart failure and/or stroke care programmes. Even though the details of such integrated AF management programmes will vary locally and await optimisation by research<sup>2,95,96</sup>, there is already a strong case underpinning integrated AF care programmes. Figure 3 outlines aspects of the current structure of AF care and the general structure of integrated AF care. A few key features of integrated AF care can be defined:

1. The diagnosis of atrial fibrillation needs to be established by ECG before treatment can start.
2. Integrated AF care provides easy access to AF care for all AF patients, close to where they live (Figure 3). Processes and infrastructures ensure that all patients in need for treatment in each of the five domains of AF care receive the care they need.
3. Most initial management decisions can be made on the spot or after a few simple tests by general or acute physicians or experienced, specially trained nurses, including anticoagulation, antihypertensive therapy, life style advice, and initiation of rate control therapy. Regular follow-up visits that can also be performed locally, e.g. by nurses, pharmacists, general practitioners, and other health care professionals working within an integrated AF care framework.
4. Integrated AF care requires good communication between all stake holders. Such communication will benefit from a common IT infrastructure, e.g. tools used by patients and health care professionals. The European Society of Cardiology, supported by the CATCH ME consortium ([www.catch-me.eu](http://www.catch-me.eu)), has provided two exemplary IT tools supporting integrated AF care for smartphones. They provide the essential knowledge to highlight AF management domains and to propose common solutions in line with evidence-based care.
5. Specialist cardiology input and cardiac imaging (usually by transthoracic echocardiography) will be beneficial during the initiation of AF management in most patients. This can be provided remotely in collaborative teams.
6. Shared decision making, putting the patient at the centre of the care process and involving families and carers, has the potential to increase adherence to chronic therapy.<sup>141</sup> Hence, shared decision making should be part of integrated care. Documenting this process will

benefit from a validated capture of patient-reported outcomes.<sup>142,143</sup> Adequately informed patients will be able to “own” the day-to-day management of AF, thereby ensuring adherence to chronic therapy.

7. Patients who develop problems or complications on therapy and those who remain symptomatic should be managed with adequate specialist input, culminating in hospital care and multidisciplinary AF Heart Teams to guide and inform difficult management decisions in selected AF patients (Figure 3). Teamwork across disciplines and care boundaries can replace the current emphasis on triaging of patients.
8. Integrated AF care programmes provide all AF patients access to research projects in AF, thus providing patients the choice to participate in such research projects and contributing to the further development of AF care.
9. Integrated AF care structures allow to measure and improve quality of care<sup>144</sup> with a denominator that is reflecting the AF population.

**Stratified therapy of AF patients considering drivers of AF.** Integrated AF care has the aim to render the best current AF therapy accessible for all AF patients in an efficient way. Even the best AF therapy, e.g. delivered in controlled clinical trials or in specialized centres, is only partially effective in preventing AF-related complications.<sup>2,11,12,72</sup> Applying potentially effective therapies to large, unselected AF patient cohorts can completely avert expected treatment effects.<sup>145-148</sup> We currently do not have reliable methods to determine which AF patient will respond well to which therapy. This is particularly challenging for rate and rhythm control therapy. Hence, we are beginning to develop stratified or personalized approaches to AF therapy, and the tools to underpin such therapies are not available in full.<sup>149</sup> AF clinicians and researchers recognise that AF is caused by different disease drivers in different patients, and that these differences can be used to develop stratified approaches to AF management.<sup>150</sup> Unfortunately, different drivers for AF will overlap in individual patients<sup>144,150</sup>, and AF-inflicted damage will contribute common elements to cardiac dysfunction.<sup>47,151-153</sup> Still, a few examples exist where mechanism-based stratification of AF therapy has been successfully translated into clinical management:

- Obese patients with AF benefit from structured weight reduction and fitness programmes, at times even obviating the need for scheduled AF ablation procedures.<sup>61-63</sup> It is not unlikely that fatty infiltration of the atria and activation of atrial adipocytes<sup>59,60</sup> mediate the “proarrhythmic” effect of obesity, and the antiarrhythmic effects of weight loss.
- Sodium channel gene variants or mutations are not infrequent in patients with early-onset AF<sup>154-158</sup>, and inherited arrhythmogenic diseases conveyed by sodium channel mutations include early-onset AF in their phenotype.<sup>159-161</sup> Sodium channel modulating ion channel blockers could be a promising treatment for such patients to prevent AF<sup>162,163</sup>, similar to the effect of similar substances to prevent ventricular arrhythmias. The ESC AF guidelines suggest to actively assess the ECG and echocardiogram for such inherited conditions leading to AF, especially in young patients presenting with AF. Recent data furthermore suggest that common gene variants associated with AF can also modify the response to sodium channel blockers.<sup>164</sup>
- ACE inhibitors can prevent incident AF in patients with left ventricular hypertrophy<sup>52</sup> and those with markedly reduced left ventricular function<sup>165</sup>, while the same treatment does not prevent recurrent AF in other patients.<sup>147,148</sup> This suggests that inhibition of the renin-angiotensin system can prevent some forms of atrial cardiomyopathy<sup>166</sup>, while the therapy seems without effect in patients without atrial damage mediated by activation of the renin-angiotensin system.

Clearly, these examples can only illustrate how different types of AF, differentiated by the major pathophysiological drivers of the arrhythmia in individual patients, could potentially be used to develop personalised treatment concepts for atrial fibrillation in the future.<sup>149</sup> Ongoing research programmes will need to translate mechanistic insights into AF and its complications into clinical management concepts to unleash the full potential of personalized AF management. Integration of specialist knowledge and AF Heart Teams into clinical care will be the key to support these developments and to adjust them to clinical needs.

**In summary,**

- I. Screening for silent AF emerges as an important opportunity to prevent AF-related complications.
- II. All AF patients should receive long-term treatment in five domains (Figure 2):
  1. Acute hemodynamic stabilization
  2. Detection and treatment of concomitant cardiovascular diseases
  3. Assessment of stroke risk and (in most patients) oral anticoagulation
  4. Assessment of ventricular rate and (in most patients) rate control therapy
  5. Assessment of symptoms related to AF and rhythm control therapy in those with AF-related symptoms.
- III. Successful AF management relies on integration of the following components (Figure 3)
  1. timely detection of AF (ideally prior to the first complication)
  2. provision of chronic support for the care of all AF patients,
  3. active patients who “own” their management,
  4. measurable quality of care,
  5. access to all treatment options for all AF patients,
  6. early identification and fast-track triaging of patients in need for specialist interventions,
  7. multidisciplinary AF Heart Teams informing difficult management decisions, and
  8. integration of clinical research projects into AF care programmes, e.g. developing stratified approaches to management.

This can best be provided by integrated care provided by interdisciplinary and cross-sector health care teams including pharmacists, nurses, general physicians, and AF specialists (Figure 3). Difficult decisions will arise in some patients and should be guided by advice from AF Heart teams comprising specialists in stroke prevention, stroke therapy, rate and rhythm control therapy, interventional and surgical treatment of AF.

- IV. Future improvements will require a new taxonomy of AF identifying the major causes of AF in individual patients and the development and systematic evaluation of stratified AF therapy.



**Search strategy.** We searched the Cochrane Library (date range), MEDLINE (date range), and EMBASE (date range), supplemented by publications known to the author were necessary. We used the search terms “atrial fibrillation” combined with “stroke prevention”, “risk factor”, “rate control”, “rhythm control”, “anticoagulation”, “combination therapy”, “stroke”, “occluder”, “ablation”, or “surgery” where required. We largely selected publications in the past 6 years based on novelty, citations, and relevance for this clinical seminar, but did not exclude commonly referenced and highly regarded older publications. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Review articles and book chapters are cited to provide readers with more details and more references than this Seminar has room for. Our reference list was modified on the basis of comments from peer reviewers.

**Sources of funding.** This seminar was written with supported by European Union (grant agreement No 633196 [CATCH ME]), British Heart Foundation (FS/13/43/30324), and Leducq Foundation. AFNET is partly funded by the DZHK (German Center for Cardiovascular Research) funded by BMBF. I would like to thank Dipak Kotecha for providing the CT image of the heart (Figure 1) and for help with preparing the figures.

## Legends to Figures

**Figure 1:** Main treatment options in the different domains of AF management and their cardiac targets. Shown is a CT image of a heart in an oblique and rotated view showing all four heart chambers, the pulmonary veins, the left atrial appendage, and the atrio-ventricular node. Boxes depict commonly used therapies and interventions in patients with atrial fibrillation. Arrows point to the main target of those therapies. Solid lines point to established treatment targets, dashed lines indicate potential additional treatment targets. AVN Atrio ventricular node, LA left atrium, LAA left atrial appendage, LV left ventricle. PV pulmonary veins, RA right atrium, RV right ventricle. CT image provided by Dr Dipak Kotecha, Birmingham.

**Figure 2:** The five domains of AF management. AF patients require acute hemodynamic stabilization (depending on clinical presentation), detection treatment of concomitant cardiovascular conditions, stroke risk assessment and decision on oral anticoagulation therapy. These treatment domains have the potential to improve prognosis. Most AF patients also require rate control therapy, and those who are symptomatic will need rhythm control therapy to improve symptoms. Reproduced from <sup>2</sup>, adapted from <sup>167</sup>.

**Figure 3:** Structure of Integrated AF Care (bottom panel) compared to current AF care (top panel). Current care models provide different access points for care, including no access, general practice / internists, office based cardiologists / cardiology outpatients, TIA and stroke services, emergency and acute medicine departments, and hospital-based cardiology and electrophysiology departments. Patients are often not put in contact with the team that can provide the best care for them, and follow-up is not structured across disciplines or sectors. Recently, many examples of better integration of AF care have been described. Integrated AF care (bottom panel) provides a common access point for all patients with AF, where initial assessment and therapy is delivered. The process of engaging and empowering patients is started here. Patients are then fast-tracked to receive appropriate further input into their treatment which may be continued in the community or supported by general practitioners, outpatient cardiologists, hospital-based specialties, or even AF Heart Teams providing input into difficult decisions and access to subspecialist interventions. Bringing health care professionals closer to the patient, ideally in the communities where they live, and working as a team supported by an IT infrastructure across disciplines and health care sectors are key components of integrated AF care. Such a service fulfils the quality criteria for a good AF service: Provision of all therapy options for all patients, measurable quality of care, multidisciplinary decision making when needed, and a service that is accessible to all AF patients. At the same time, reorganisation has the potential to manage more patients in the community, thus taking pressure off hospitals and specialist services. Integrated care will also allow to measure and improve quality of care across entire catchment areas.<sup>144</sup> Furthermore, integrated AF care is conducive to innovation and research, e.g stratified therapy of AF patients. C counsellor, N nurse, O other health care professional, P physician, S specialist doctor.

## References

1. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* 2015; **386**(9989): 154-62.
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; **37**(38): 2893-962.
3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2014; **129**(8): 837-47.
4. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. *Heart* 2004; **90**(3): 286-92.
5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ Cardiovasc Qual Outcomes* 2011; **4**(3): 313-20.
6. Chao TF, Liu CJ, Chen SJ, et al. CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. *Int J Cardiol* 2013; **168**(2): 1360-3.
7. (WHO) WHO. Global Action Plan on the prevention and control of noncommunicable diseases. 2013 (accessed 18 September 2016).
8. Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. *Europace* 2014; **16**(7): 965-72.
9. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. *Ann Intern Med* 2007; **147**(8): 590-2.
10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; **383**(9921): 955-62.
11. Marijon E, Le Heuzey JY, Connolly S, et al. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation: A Competing Risk Analysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study. *Circulation* 2013; **128**(20): 2192-201.
12. Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Eur Heart J* 2016.
13. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. *Europace* 2009; **11**: 423-34.
14. Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Am Heart J* 2014; **167**(5): 735-42 e2.
15. Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). *Eur Heart J* 2014; **35**(47): 3365-76.
16. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events--European Registry in Atrial Fibrillation (PREFER in AF). *Europace* 2014; **16**(1): 6-14.
17. Meinertz T, Kirch W, Rosin L, et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. *Clin Res Cardiol* 2011; **100**(10): 897-905.
18. Steg PG, Alam S, Chiang CE, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. *Heart* 2012; **98**(3): 195-201.
19. Frasure-Smith N, Lesperance F, Talajic M, et al. Anxiety sensitivity moderates prognostic importance of rhythm-control versus rate-control strategies in patients with atrial fibrillation and

congestive heart failure: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. *Circ Heart Fail* 2012; **5**(3): 322-30.

20. von Eisenhart Rothe AF, Goette A, Kirchhof P, et al. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. *Europace* 2014; **16**(6): 812-9.
21. Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. *Stroke* 2011; **42**(10): 2866-71.
22. Lange HW, Herrmann-Lingen C. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. *J Psychosom Res* 2007; **63**(5): 509-13.
23. Sang CH, Chen K, Pang XF, et al. Depression, anxiety, and quality of life after catheter ablation in patients with paroxysmal atrial fibrillation. *Clin Cardiol* 2013; **36**(1): 40-5.
24. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. *Lancet* 2013; **381**(9862): 242-55.
25. Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. *Europace* 2013; **15**(10): 1389-406.
26. Reinier K, Marijon E, Uy-Evanado A, et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. *JACC Heart failure* 2014; **2**(3): 221-7.
27. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med* 2009; **360**(7): 668-78.
28. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014; **384**(9961): 2235-43.
29. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. *Stroke* 2013; **44**(12): 3357-64.
30. Rizos T, Guntner J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. *Stroke* 2012; **43**(10): 2689-94.
31. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). *Eur Heart J* 2007; **28**(22): 2803-17.
32. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. *Circulation* 2015; **131**(25): 2176-84.
33. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). *Europace* 2013; **15**(1): 135-40.
34. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. *Circulation* 2015.
35. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ* 2007; **335**(7616): 383.
36. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014; **130**(23): e199-267.
37. Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. *Europace* 2015.
38. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol* 2015; **14**(4): 377-87.

39. Stahrenberg R, Weber-Kruger M, Seegers J, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. *Stroke* 2010; **41**(12): 2884-8.
40. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014; **370**(26): 2478-86.
41. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med* 2014; **370**(26): 2467-77.
42. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. *Lancet Neurol* 2014; **13**(4): 429-38.
43. Wachter R, Groschel K, Gelbrich G, et al. Holter monitoring in acute ischaemic stroke (Find-AFRANDOMISED): a randomised trial. *Lancet Neurol* 2017; **in press (accepted 23 Dec 2016)**.
44. Haeusler KG, Kirchhof P, Heuschmann PU, et al. Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. *Am Heart J* 2016; **172**: 19-25.
45. Diener HC, Easton JD, Granger CB, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). *Int J Stroke* 2015; **10**(8): 1309-12.
46. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. *Eur Stroke J* in press; **doi: 10-1177/2396987316663049**.
47. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. *Eur Heart J* 2009; **30**(24): 2969-77c.
48. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation - results of the XPECT trial. *Circ Arrhythm Electrophysiol* 2010; **3**(2): 141-7.
49. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). *Eur Heart J* 2016: published on line 28 August 2016, 10.1093/eurheartj/ehw210.
50. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). *Eur Heart J* 2016: published 27 August 2016, 10.1093/eurheartj/ehw210.
51. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. *Europace* 2012; **14**(1): 8-27.
52. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol* 2005; **45**(5): 712-9.
53. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. *Eur Heart J* 2014; **35**(18): 1205-14.
54. Suarez J, Piccini JP, Liang L, et al. International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. *Am Heart J* 2012; **163**(5): 804-11.
55. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the

special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016; **37**(27): 2129-200.

56. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? *Eur Heart J* 2015.

57. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014.

58. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. *N Engl J Med* 2013; **369**(13): 1206-14.

59. Gaborit B, Venteclef N, Ancel P, et al. Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, peri-ventricular, or peri-coronary location. *Cardiovasc Res* 2015; **108**(1): 62-73.

60. Venteclef N, Guglielmi V, Balse E, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokinases. *Eur Heart J* 2015; **36**(13): 795-805a.

61. Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. *J Am Coll Cardiol* 2015; **66**(9): 985-96.

62. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). *J Am Coll Cardiol* 2015; **65**(20): 2159-69.

63. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013; **310**(19): 2050-60.

64. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013; **381**(9872): 1107-15.

65. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. *Circulation* 2013; **127**(5): 634-40.

66. Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013; **34**(38): 2949-3003.

67. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N Engl J Med* 2016; **375**(25): 2423-34.

68. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol Rev* 2011; **91**(1): 265-325.

69. Hankey GJ. Stroke. *Lancet* 2016.

70. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. *Lancet* 2016; **388**(10046): 806-17.

71. Allan V, Banerjee A, Shah AD, et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. *Heart* 2016.

72. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015; **131**(2): 157-64.

73. Camm AJ, Amarencio P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J* 2016; **37**(14): 1145-53.

74. Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart J* 2016.

75. Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet* 2016; **387**(10035): 2302-11.

76. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. *Eur Heart J* 2016.
77. Budera P, Straka Z, Osmancik P, et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. *Eur Heart J* 2012; **33**(21): 2644-52.
78. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. *Am Heart J* 2005; **150**(2): 288-93.
79. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. *Eur J Cardiothorac Surg* 2015; **47**(5): 847-54.
80. Whitlock RP, Vincent J, Blackall MH, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). *Can J Cardiol* 2013; **29**(11): 1443-7.
81. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. *N Engl J Med* 2015; **372**(15): 1399-409.
82. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2010; **3**(6): 624-31.
83. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation* 2007; **115**(21): 2689-96.
84. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. *Circ Cardiovasc Qual Outcomes* 2013; **6**(5): 567-74.
85. Bertozzo G, Zoppellaro G, Granziera S, et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. *J Thromb Haemost* 2016; **14**(11): 2124-31.
86. Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. *Thromb Haemost* 2016; **115**(5): 939-49.
87. Wang ZZ, Du X, Wang W, et al. Long-Term Persistence of Newly Initiated Warfarin Therapy in Chinese Patients With Nonvalvular Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes* 2016; **9**(4): 380-7.
88. Hanon O, Vidal J, Le Heuzey J, et al. Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. *Heart* 2017; **in press**.
89. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 survey of atrial fibrillation and stroke: Gaps in knowledge and perspective, opportunities for improvement. *Heart Rhythm* 2015; **12**(8): e105-13.
90. Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. *Thromb Haemost* 2014; **111**(5): 833-41.
91. O'Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. *Am Heart J* 2014; **167**(4): 601-9 e1.
92. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. *J Thromb Haemost* 2015; **13**(4): 495-504.
93. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA* 2015; **313**(8): 824-36.

94. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. *Circulation* 2015; **132**(6): 517-25.
95. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. *Eur Heart J* 2012; **33**(21): 2692-9.
96. Stewart S, Ball J, Horowitz JD, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. *Lancet* 2015; **385**(9970): 775-84.
97. Berti D, Hendriks JM, Brandes A, et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. *Eur Heart J* 2013.
98. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010; **362**(15): 1363-73.
99. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. *BMJ* 2015; **351**: h4451.
100. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. *J Am Coll Cardiol* 1999; **33**(2): 304-10.
101. Van Gelder I, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med* 2002; **347**: 1834-40.
102. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; **347**(23): 1825-33.
103. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet* 2000; **356**(9244): 1789-94.
104. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. *Lancet* 2016; **388**(10046): 818-28.
105. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. *Am Heart J* 2013; **166**(3): 442-8.
106. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. *Lancet* 2016; **388**(10046): 829-40.
107. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. *Circulation* 2000; **101**(11): 1282-7.
108. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. *Lancet* 2002; **360**(9342): 1275-9.
109. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. *Lancet* 2012; **380**(9838): 238-46.
110. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. *Eur Heart J* 2004; **25**(16): 1385-94.
111. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. *N Engl J Med* 2004; **351**(23): 2384-91.
112. Lown B, Perlroth M, Kaidbey S, Abe T, Harken DE. Cardioversion of atrial fibrillation. A report on the treatment of 65 episodes in 59 patients. *N Engl J Med* 1963; **269**: 325-31.
113. Rossi M, Lown B. The use of quinidine in cardioversion. *Am J Cardiol* 1967; **19**(2): 234-8.
114. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet* 2016.



115. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. *J Am Coll Cardiol* 2003; **41**(2): 255-62.
116. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. *N Engl J Med* 2005; **352**(18): 1861-72.
117. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. *J Am Coll Cardiol* 2011; **57**(3): 313-21.
118. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *N Engl J Med* 2000; **342**(13): 913-20.
119. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med* 2008; **358**(25): 2667-77.
120. Käb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. *Eur Heart J* 2003; **24**(7): 649-57.
121. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in High-Risk Permanent Atrial Fibrillation. *N Engl J Med* 2011; **365**(24): 2268-76.
122. Darkner S, Chen X, Hansen J, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). *Eur Heart J* 2014; **35**(47): 3356-64.
123. Darkner S, Chen X, Hansen J, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). *Eur Heart J* 2014.
124. Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. *Ann Thorac Surg* 1993; **56**(4): 814-23.
125. Huffman MD, Karmali KN, Berendsen MA, et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. *Cochrane Database Syst Rev* 2016; (8): CD011814.
126. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998; **339**(10): 659-66.
127. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace* 2012; **14**(4): 528-606.
128. Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. *Eur Heart J* 2016.
129. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. *N Engl J Med* 2012; **367**(17): 1587-95.
130. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *JAMA* 2014; **311**(7): 692-700.
131. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. *N Engl J Med* 2016.
132. Mont L, Bisbal F, Hernandez-Madrid A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). *Eur Heart J* 2014; **35**(8): 501-7.
133. Amit G, Nyong J, Morillo CA, et al. Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillation. *Cochrane Database Syst Rev* 2016; **DC012088**: doi:10.1002/14561858.CD012088.pub2.
134. Arbelo E, Brugada J, Hindricks G, et al. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. *Eur Heart J* 2014; **35**(22): 1466-78.

135. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med* 2015; **372**(19): 1812-22.
136. Kuck KH, Hoffmann BA, Ernst S, et al. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. *Circ Arrhythm Electrophysiol* 2016; **9**(1): e003337.
137. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. *Am J Med* 2015; **128**(12): 1306-13 e1.
138. Page K, Marwick TH, Lee R, et al. A systematic approach to chronic heart failure care: a consensus statement. *Med J Aust* 2014; **201**(3): 146-50.
139. Stock S, Pitcavage JM, Simic D, et al. Chronic care model strategies in the United States and Germany deliver patient-centered, high-quality diabetes care. *Health Aff (Millwood)* 2014; **33**(9): 1540-8.
140. Lundstrom H, Siersma V, Nielsen AB, et al. The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP). *Diabetologia* 2014; **57**(6): 1119-23.
141. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. *Circulation* 2014; **129**(6): 704-10.
142. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 2013; **309**(8): 814-22.
143. Anker SD, Agewall S, Borggrefe M, et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. *Eur Heart J* 2014; **35**(30): 2001-9.
144. Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. *Europace* 2016; **18**(1): 37-50.
145. Jackson N, Atar D, Borentain M, et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. *Eur Heart J* 2015.
146. Zheng Z, Jayaram R, Jiang L, et al. Perioperative Rosuvastatin in Cardiac Surgery. *N Engl J Med* 2016; **374**(18): 1744-53.
147. Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. *N Engl J Med* 2011; **364**(10): 928-38.
148. Goette A, Schon N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. *Circ Arrhythm Electrophysiol* 2012; **5**(1): 43-51.
149. Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. *Eur Heart J* 2014; **35**(46): 3250-7.
150. Fabritz L, Guasch E, Antoniades C, et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. *Nat Rev Cardiol* 2016; **13**(4): 230-7.
151. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995; **92**(7): 1954-68.
152. Van Gelder IC, Haegeli LM, Brandes A, et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. *Europace* 2011; **13**(11): 1517-25.
153. Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. *Eur Heart J* 2014; **35**(22): 1448-56.
154. Watanabe H, Yang T, Stroud DM, et al. Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. *Circulation* 2011; **124**(9): 1001-11.
155. Olesen MS, Jespersen T, Nielsen JB, et al. Mutations in sodium channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation. *Cardiovasc Res* 2011; **89**(4): 786-93.

156. Makiyama T, Akao M, Shizuta S, et al. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. *J Am Coll Cardiol* 2008; **52**(16): 1326-34.
157. Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. *Circulation* 2008; **117**(15): 1927-35.
158. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. *JAMA* 2005; **293**(4): 447-54.
159. Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. *J Am Coll Cardiol* 2008; **51**(12): 1169-75.
160. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. *Heart Rhythm* 2008; **5**(5): 704-9.
161. Zellerhoff S, Pistulli R, Monnig G, et al. Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. *J Cardiovasc Electrophysiol* 2009; **20**(4): 401-7.
162. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. *Br J Pharmacol* 2006; **148**(1): 16-24.
163. Lemoine MD, Duverger JE, Naud P, et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. *Cardiovasc Res* 2011; **92**(1): 67-74.
164. Syeda F, Holmes AP, Yu TY, et al. PITX2 modulates atrial membrane potential and reduced PITX2 potentiates the antiarrhythmic effects of sodium-channel blockers. *JACC* 2016; **68**: 59-72; doi: 10.1016/j.jacc.2016.07.766.
165. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. *Eur Heart J* 1999; **20**(10): 748-54.
166. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. *Europace* 2016.
167. Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. *Europace* 2013; **15**(11): 1540-56.

Figures 1 and 2 R1




Figure 1






Figure 2

 Adequately managed AF patients

 AF patients in need of better management

 AF patients needing specialist intervention

[illegible]

**General practice**

**Outpatient cardiology**

**Stroke Medicine**

**Cardiology & Electrophysiology**

**General Medicine**

**Emergency Department**

**AF Heart Team**

- Electrophysiology
- Complex anticoagulation
- Revascularisation
- Structural intervention
- Surgery

**Access to integrated AF care in the community**  
Including Cardiologist, General physicians and AF nurses